FTT sure is friendless at the moment. Only around 5 million shares have traded altogether in last 6 weeks, or $300,000 worth at today's price.
Not even Bioshares picking FTT as one of their 6 top biotechs for 2017 managed to attract any buying interest.
This is a bit surprising because Bioshares seems to be remarkably clever at picking the top 6 biotechs for each year:
I was stunned when I read their track record:
Bioshares Top 6 Stock Pick Track Record
2016 83.7%
2015 53.1%
2014 40.8%
2013 62.2%
2012 36.2%
oh well...
- Forums
- ASX - By Stock
- DLM
- Ann: Phase II Clinical Trial - First Patient In
Ann: Phase II Clinical Trial - First Patient In, page-7
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DLM (ASX) to my watchlist
|
|||||
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.227M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
DLM (ASX) Chart |
Day chart unavailable